Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate

Leri, O; Tubili, S; Rosa, Francesco Giuseppe De; Addessi, Maria Assunta; Scopelliti, G; Lucenti, W.; Luca, Diana

doi:10.1007/s10787-997-0024-7

Cited by 22 publications

(33 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positive skin prick testing for common food antigens has been reported in up to a third of patients with IBS and these patients have been reported to respond better to elimination diet and type I hypersensitivity inhibitors such as sodium cromoglycate 103. These results need confirming before definitive conclusions can be drawn 104. It should be recognised that in only a minority of cases is the patient's beliefs confirmed objectively, so some of their response must be psychologically determined.…”

Section: 0 Aetiologymentioning

confidence: 99%

British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome

Jones

Boorman²,

Cann³

et al. 2000

Gut

148

110

View full text Add to dashboard Cite

Section: 0 Aetiologymentioning

confidence: 99%

British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome

Jones

Boorman²,

Cann³

et al. 2000

Gut

148

110

View full text Add to dashboard Cite

“…Six months later, DSCG was associated with reduced release of tryptase from jejunal biopsies, reduced expression of TLR2 and TLR4, and improved bowel function (52,53). In an earlier study of 66 IBS-D patients with food intolerance assessed by skin prick test, DSCG (250 mg, 4 times per day) plus exclusion diet was associated with prolonged symptomatic benefit compared with exclusion diet alone (54).…”

Section: Chronic Diarrheamentioning

confidence: 93%

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

Camilleri¹

2013

J. Clin. Invest.

View full text Add to dashboard Cite

Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. IntroductionGastrointestinal motility and functional disorders result in either abnormal propulsion of content or excessive sensation of normal or abnormal functions in different regions of the gut. These conditions constitute about 40% of referrals to gastroenterologists, and they result in significant disease burden. Advances in clinical management of these disorders are based on understanding the basic mechanisms involved in sensorimotor and secretory functions, coupled with clinical investigation and trial methodology.The most frequent gastrointestinal motility and functional disorders are esophagitis, gastroparesis, chronic diarrhea, chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), and visceral pain. This review summarizes the pathophysiology, lists commonly used current medications, and focuses on pharmacological agents in development for each disorder. At present, several approved medications relieve constipation and diarrhea; the major unmet needs are in gastroparesis, OIC, and visceral pain.

show abstract

“…Article Conclusion Leri et al [116] Efficient (in conjunction with dietary exclusions in IBS patients with food intolerance) …”

Section: Cromoglycatementioning

confidence: 99%

Inflammation as a Potential Therapeutic Target in IBS

Chira¹,

Chira²,

Dumitraşcu³

2016

Irritable Bowel Syndrome - Novel Concepts for Research and Treatment

View full text Add to dashboard Cite

The pathogenesis of irritable bowel syndrome (IBS) has been intensively researched, and despite a long journey for unraveling all the structures and the pathways involved, it still remains partially obscure. Inflammation was the first to be hypothesized as a potential pathway for the pathogenesis of IBS. It remains a keystone in the complex machinery of the pathogenesis that is currently considered multifactorial. Elucidating the pathogenesis of IBS is crucial for a targeted therapy of the disease. In this chapter, we review information regarding gut inflammation in IBS, underlining some of the newest data or the cornerstones. Additionally, our aim was also to review treatment currently available and future perspectives regarding anti-inflammatory treatments for IBS. Newer techniques allow detection and research of mediators involved in inflammation, as well as their potential role to be targeted by pharmacological agents. Recent data supports not only further research of the newer agents that are currently being developed but also some of the available ones that do not have sufficient evidence. Emerging therapies that target inflammation are under evaluation, in trials. A multidrug or a multidisciplinary approach needs to be considered in some cases that fail to respond to current treatment.

show abstract

Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate

Cited by 22 publications

References 11 publications

British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome

British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

Inflammation as a Potential Therapeutic Target in IBS

Contact Info

Product

Resources

About